Mariprax (Pramipexole Dihydrochloride Monohydrate)

Pramipexole binds to dopamine D2 and D3 receptors, especially in the basal ganglia, mimicking dopamine activity. This stimulation restores dopaminergic signaling that is deficient in Parkinsonian disorders, helping to improve motor control and reduce restless leg symptoms.

The specific dose of Mariprax is determined by the prescribing clinician based on the patient’s condition, response, and tolerability. Dosage adjustments are made during treatment to achieve optimal therapeutic effect while minimizing side effects.

Safety of pramipexole in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Mariprax, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mariprax (pramipexole) is a non‑ergot dopamine agonist, offering once‑daily dosing and a lower risk of certain side effects compared with some older agents like bromocriptine. It is often used as an adjunct to levodopa or as monotherapy in early disease, providing a different side‑effect profile than MAO‑B inhibitors.

Mariprax should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain potency throughout its shelf life.

Mariprax is taken orally, usually with or without food, as directed by the prescriber. Tablets are swallowed whole with a glass of water; they should not be crushed, chewed, or divided unless specifically instructed.

Serious risks include hallucinations, impulse‑control disorders (such as compulsive gambling or shopping), sudden onset of sleep, severe depression, and rare cases of suicidal thoughts. Patients should be monitored closely for any of these symptoms, especially during dose adjustments.

Mariprax is contraindicated in patients with known hypersensitivity to pramipexole or any of its excipients, and it should be avoided in individuals taking MAO‑B inhibitors. Caution is also advised for patients with severe renal impairment or a history of psychosis.